Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Allogene
Allogene
1 article from Allogene indexed by Voice Herald. Below is what Allogene covers most and which stories they have contributed to.